

Reference:	FOI.11718.23
Subject:	Endometrial cancer
Date of Request:	18 May 2023

Requested:

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

Dostarlimab
Hormone therapy (Progesterone or Letrozole)
Pembrolizumab monotherapy
Pembrolizumab in combination with Lenvatinib
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
Any other SACT
3. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:

Hormone therapy (Progesterone or Letrozole)
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
Any other SACT
4. Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part

Response:

Hywel Dda University Health Board (UHB) does not hold the information for all GP Surgeries, as with the exception of the Managed Practices, they are all managed independently. These GP Practices hold their own information and consequently, the UHB does not have access to all of the details you require. Therefore, this information would need to be requested directly from the individual GP Practices. A link to all the GP surgeries in the UHB's geographical area has been provided below:

<http://www.wales.nhs.uk/sitesplus/862/directory/gps/>

Additionally, the UHB is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working

days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of endometrial cancer patients treated with hormone therapy (Progesterone or Letrozole) for questions 2 and 3, the UHB would need to undertake a manual trawl of all of the identified prescriptions and cross-reference with the patient's medical record, to identify any information that would fulfil your request.

However, the UHB can confirm that a total of eight thousand seven hundred and seventy nine (8,779) hormone therapy prescriptions were issued by the Primary Care Pharmacy Department, during the six (6) month period of 1 October 2022 to 31 March 2023. Details of these are:

- Medroxyprogesterone 128 prescriptions
- Megestrol 38 prescriptions
- Letrozole 8,613 prescriptions

Therefore, to provide you with the exact information being requested, conducting the search would far exceed the 'appropriate limit', costing the UHB the following:

8,779 @ 15 minutes per item = 2,194.75 hours
2,194.75 hours @ £25 per hour = £54,868.75

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

Furthermore, the UHB is withholding the detail requested for question 4 under Section 40(2) of the FoIA and has replaced the figures in the table with an asterisk (*), as the UHB is unable to provide you with the exact numbers, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed.

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB has provided the accessible information it holds below.

1. The UHB confirms that it does provide systemic anti-cancer therapy (SACT) treatments for endometrial cancer.
2. The UHB provides, within the table below, the number of patients treated for endometrial cancer with the listed medications, as recorded on the ChemoCare system, during the period 1 December 2022 to 31 May 2023.

Medication	Number
Dostarlimab	*
Hormone therapy (Progesterone or Letrozole)	Section 12
Pembrolizumab monotherapy	*
Pembrolizumab in combination with Lenvatinib	*
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	14
Any other SACT	6

3. The UHB provides, within the table below, the number of endometrial cancer patients that received the listed therapies as a first line treatment, as recorded on the ChemoCare system, during the period 1 December 2022 to 31 May 2023.

Medication	Number
Hormone therapy (Progesterone or Letrozole)	Section 12
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	10
Any other SACT	*

4. S40 exemption applied.
5. The UHB confirms that no commercial SACT trials are currently open on the ChemoCare system for endometrial cancer.